A detailed history of Cibc Bancorp Usa Inc. transactions in Taysha Gene Therapies, Inc. stock. As of the latest transaction made, Cibc Bancorp Usa Inc. holds 29,476 shares of TSHA stock, worth $124,093. This represents 0.0% of its overall portfolio holdings.

Number of Shares
29,476
Holding current value
$124,093
% of portfolio
0.0%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 21, 2025

SELL
$2.34 - $3.29 $15,989 - $22,480
-6,833 Reduced 23.18%
22,643 $71,000
Q3 2025

Nov 12, 2025

BUY
$2.34 - $3.29 $68,973 - $96,976
29,476 New
29,476 $92,000

Others Institutions Holding TSHA

About Taysha Gene Therapies, Inc.


  • Ticker TSHA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 48,359,500
  • Market Cap $204M
  • Description
  • Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for th...
More about TSHA
Track This Portfolio

Track Cibc Bancorp Usa Inc. Portfolio

Follow Cibc Bancorp Usa Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cibc Bancorp Usa Inc., based on Form 13F filings with the SEC.

News

Stay updated on Cibc Bancorp Usa Inc. with notifications on news.